Relmada Therapeutics Analyst Ratings and Price Targets | NASDAQ:RLMD | Benzinga

Relmada Therapeutics Inc has a consensus price target of $10.33 based on the ratings of 6 analysts. The high is $26 issued by Mizuho on June 15, 2023. The low is $1 issued by Leerink Partners on December 4, 2024. The 3 most-recent analyst ratings were released by Mizuho, Mizuho, and Leerink Partners on November 19, 2025, December 5, 2024, and December 4, 2024, respectively. With an average price target of $4 between Mizuho, Mizuho, and Leerink Partners, there's an implied -7.83% downside for Relmada Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

Nov

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.2

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

Mizuho

Leerink Partners

Jefferies

Goldman Sachs

Mizuho

¹calculated from analyst ratings

Analyst Ratings for Relmada Therapeutics

					Get Alert
Nov 19, 2025	130.41%	Uy EarMizuho 64%	1 10	Previous Neutral Current Outperform	Get Alert
Dec 5, 2024	-76.96%	Uy EarMizuho 64%	1 23	Previous Outperform Current Neutral	Get Alert
Dec 4, 2024	-76.96%	Marc GoodmanLeerink Partners 74%	1 10	Previous Outperform Current Market Perform	Get Alert
Sep 17, 2024	199.54%	Andrew TsaiJefferies 44%	3.5 13	Previous Hold Current Buy	Get Alert
Jun 5, 2024	-53.92%	Andrea TanGoldman Sachs 44%	2 3	Previous Neutral Current Sell	Get Alert
Jun 15, 2023	499.08%	Vamil DivanMizuho 80%	26	Previous Buy Current Buy	Get Alert
Jan 23, 2023	130.41%	Marc GoodmanSVB Leerink 74%	10 42	Previous Current Outperform	Get Alert

FAQ

What is the target price for Relmada Therapeutics (RLMD) stock?

The latest price target for Relmada Therapeutics (NASDAQ:RLMD) was reported by Mizuho on November 19, 2025. The analyst firm set a price target for $10.00 expecting RLMD to rise to within 12 months (a possible 130.41% upside). 1 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Relmada Therapeutics (RLMD)?

The latest analyst rating for Relmada Therapeutics (NASDAQ:RLMD) was provided by Mizuho, and Relmada Therapeutics upgraded their outperform rating.

When was the last upgrade for Relmada Therapeutics (RLMD)?

The last upgrade for Relmada Therapeutics Inc happened on November 19, 2025 when Mizuho raised their price target to $10. Mizuho previously had a neutral for Relmada Therapeutics Inc.

When was the last downgrade for Relmada Therapeutics (RLMD)?

The last downgrade for Relmada Therapeutics Inc happened on December 5, 2024 when Mizuho changed their price target from $23 to $1 for Relmada Therapeutics Inc.

When is the next analyst rating going to be posted or updated for Relmada Therapeutics (RLMD)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relmada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relmada Therapeutics was filed on November 19, 2025 so you should expect the next rating to be made available sometime around November 19, 2026.

Is the Analyst Rating Relmada Therapeutics (RLMD) correct?

While ratings are subjective and will change, the latest Relmada Therapeutics (RLMD) rating was a upgraded with a price target of $1.00 to $10.00. The current price Relmada Therapeutics (RLMD) is trading at is $4.34, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.